Selank

About Selank peptides (research compound)

Selank peptides are synthetic heptapeptides derived from a stabilized analog of the naturally occurring immunomodulatory tetrapeptide tuftsin. Velora Research supplies Selank peptide as a 10mg lyophilized vial for in vitro and preclinical investigation by qualified laboratories and research professionals.

Every batch of Velora’s Selank peptide is independently verified by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity. The batch-specific Certificate of Analysis is published on our COAs page and linked from this product page so researchers can confirm identity, purity, and molecular integrity before placing the compound into a study.

What is Selank peptide?

Selank peptide is a synthetic seven-amino-acid heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four residues correspond to tuftsin, a naturally occurring tetrapeptide originally identified as an immune-modulating fragment of the IgG heavy chain. The C-terminal Pro-Gly-Pro extension stabilizes the peptide against rapid enzymatic degradation, the same stabilization strategy used in the related research peptide Semax.

Selank was originally developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. The molecular weight is approximately 751.9 g/mol. In published preclinical and clinical research (primarily Russian and Eastern European groups), Selank peptide has been characterized as a regulatory peptide acting on multiple signaling systems, with documented effects in cell-culture and animal models that include the GABA system, monoaminergic signaling, and immunomodulatory pathways.

Selank peptide benefits as characterized in published research

‘Selank peptide benefits’ is one of the most common search queries among researchers screening compounds for inclusion in studies. The areas of published research interest below summarize how peer-reviewed in-vitro and clinical literature has characterized the compound. All language is strict research-frame. None of these are therapeutic claims, and none describe approved Western human-use indications.

• GABA-system research. Animal-model studies of GABAergic signaling and benzodiazepine-binding-site interactions following Selank peptide administration.
• Anxiolytic research models. Animal-behavior assays characterizing Selank peptide effects in stress and anxiety research paradigms. Russian clinical data supported regional approval for generalized anxiety disorder.
• BDNF and neurotrophic-factor research. Cell-culture and animal-model studies of brain-derived neurotrophic factor expression, similar in research design to studies conducted with Semax peptide.
• Immunomodulatory research. In-vitro studies extending the published tuftsin immune-modulation research into the Selank heptapeptide structure.
• Cognitive and attention research models. Animal-behavior assays studying attention, learning, and stress-recovery paradigms.
• Monoaminergic-system research. In-vitro and animal-model investigations of dopamine and serotonin signaling pathways.

These represent published areas of research interest only. Velora Research makes no claim that Selank peptide produces any specific outcome in humans, animals, or therapeutic applications. The compound is supplied for in vitro and preclinical research investigation only.

Regulatory status: Russia and Ukraine vs United States

Selank has a regulatory profile worth understanding before purchase. In Russia and Ukraine, Selank is approved as a clinical pharmaceutical under regional regulators for specific medical indications (including generalized anxiety disorder) and is marketed under the Selank brand in an intranasal formulation. In the United States, the European Union, and most other Western jurisdictions, Selank is not approved for any therapeutic use and is supplied solely as a research compound.

Velora Research’s Selank peptide product is a research-grade compound for in vitro and preclinical laboratory investigation. It is not the same product as the Russian or Ukrainian Selank pharmaceutical, is not packaged or quality-controlled for human use, and is not for any therapeutic, nutritional, or cosmetic application.

Key specifications

Attribute	Specification
Research name	Selank peptide
Alternate names	TKPRPGP, Selank acetate
Class	Synthetic heptapeptide, stabilized tuftsin analog
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Available size	10mg
Form	Lyophilized white powder
Purity	99% or higher (HPLC verified)
Molecular formula	C33H57N11O9
Molecular weight	~751.9 g/mol
CAS number	129623-01-4
Storage (lyophilized)	-20°C, sealed, dry, dark
Storage (reconstituted)	2 to 8°C, single-use aliquots recommended
Verification	Independent third-party HPLC and mass spectrometry per batch
COA access	Batch-specific COA at verify.janoshik.com (linked from this page)

Selank peptide pricing

Velora Research lists Selank peptide 10mg at a single transparent tier. The 10mg vial is sized to cover most pilot studies and multi-arm cell-culture experiments without re-ordering:

Vial size	Price (USD)	Best for
10mg	$55.00	Pilot studies, GABA-system research models, anxiolytic-research animal assays, BDNF and neurotrophic-factor studies, immunomodulatory research

Free US shipping applies on orders over $200. Most orders process within 1 to 2 business days. International orders are accepted in accordance with applicable research regulations.

Buy Selank peptides online from Velora Research: why qualified researchers choose us

Researchers screening Selank peptide suppliers typically evaluate vendors on five criteria. Velora was built around all five:

• Batch-level third-party COA. Every lot of Selank peptide is verified by an independent analytical lab using HPLC for purity and mass spectrometry for identity. The COA is downloadable from the product page and tied to the batch number printed on the vial.
• 99% or higher HPLC-verified purity. Identity, purity, and molecular integrity confirmed before any batch is released for sale.
• Documented production protocols. Lyophilized under controlled conditions, sealed in inert atmosphere, traceable from synthesis through shipment.
• US-based 2-day shipping. Free over $200; orders processed within 1 to 2 business days.
• Compliance-first sales policy. Sales restricted to qualified laboratories, institutions, and research professionals. Research-use-only terms acknowledged at checkout.

Reconstitution and storage guidance (research use)

Velora’s Selank peptide ships as a lyophilized powder. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) or, for cell-culture protocols, with sterile water at a concentration matched to the assay. A common pilot ratio for the 10mg vial is 2 mL of bacteriostatic water, yielding a 5 mg/mL stock solution. Adjust per study design.

Published research protocols use two principal administration routes in animal-model studies: intranasal and subcutaneous. The intranasal route is used in much of the Russian Selank research literature, which also drives the high search interest in ‘selank nasal spray’ formulations. For Velora’s research-grade Selank peptide, any administration route in a research protocol should be selected and validated per the peer-reviewed literature and institutional approvals.

• Pre-reconstitution: store sealed at -20°C in a dry, dark environment. Avoid freeze-thaw cycles, which can degrade peptide integrity.
• Post-reconstitution: refrigerate at 2 to 8°C and use within the stability window established by the research protocol. Single-use aliquots reduce repeated exposure to room temperature.
• Handling: reconstitute and aliquot under sterile lab conditions with appropriate PPE.

Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.

Selank peptide vs Semax peptide: research-context comparison

Researchers evaluating Selank peptide for purchase often compare it to Semax, the other widely studied Russian-developed regulatory peptide that is also supplied by Velora Research. Summary of how the two differ at the mechanism level, drawn from published research:

Attribute	Selank peptide	Semax peptide
Origin	Synthetic tuftsin analog	Synthetic ACTH (4-7) analog
Sequence length	7 amino acids	7 amino acids
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro	Met-Glu-His-Phe-Pro-Gly-Pro
Primary research focus	Anxiolytic-research models, GABA-system research, immunomodulation research	BDNF and neurotrophic-factor research, cerebrovascular-research models, dopaminergic-system research
Regulatory status (Russia, Ukraine)	Approved clinical pharmaceutical (Selank brand)	Approved clinical pharmaceutical (Semax brand)
Regulatory status (US)	Research use only	Research use only

Both peptides are supplied by Velora Research as research compounds for in vitro and preclinical investigation only. Researchers running comparative studies of the two compounds may consider purchasing both for direct head-to-head assay designs. The compounds are often described as sister peptides because both share the C-terminal Pro-Gly-Pro stabilization extension and both originated from the same Russian research institute.